These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

773 related items for PubMed ID: 31663783

  • 1. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J, Kawalec P, Pilc A.
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC.
    JAMA Psychiatry; 2018 Feb 01; 75(2):139-148. PubMed ID: 29282469
    [Abstract] [Full Text] [Related]

  • 3. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM, Crouse EL, Titus-Lay EN, Ott CA, Nofziger JL, Kirkwood CK.
    Ann Pharmacother; 2020 Jun 01; 54(6):567-576. PubMed ID: 31795735
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB.
    JAMA Psychiatry; 2019 Sep 01; 76(9):893-903. PubMed ID: 31166571
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB.
    Int J Neuropsychopharmacol; 2019 Oct 01; 22(10):616-630. PubMed ID: 31290965
    [Abstract] [Full Text] [Related]

  • 7. Esketamine for treatment resistant depression.
    Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA, Baker G, Dursun S, Klassen LJ, Chokka P, Demas ML.
    Expert Rev Neurother; 2019 Oct 01; 19(10):899-911. PubMed ID: 31282772
    [Abstract] [Full Text] [Related]

  • 8. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T, Wajs E, Melkote R, Miller J, Singh JB, Weber MA.
    CNS Drugs; 2020 Mar 01; 34(3):299-310. PubMed ID: 31994024
    [Abstract] [Full Text] [Related]

  • 9. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F, Talreja O.
    Am J Health Syst Pharm; 2020 Aug 20; 77(17):1382-1388. PubMed ID: 32729898
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M.
    J Clin Psychiatry; 2020 May 26; 81(4):. PubMed ID: 32459407
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y.
    BMC Psychiatry; 2021 Oct 25; 21(1):526. PubMed ID: 34696742
    [Abstract] [Full Text] [Related]

  • 12. Pharmacotherapy: Ketamine and Esketamine.
    Feeney A, Papakostas GI.
    Psychiatr Clin North Am; 2023 Jun 25; 46(2):277-290. PubMed ID: 37149345
    [Abstract] [Full Text] [Related]

  • 13. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB.
    J Clin Psychiatry; 2020 Apr 28; 81(3):. PubMed ID: 32316080
    [Abstract] [Full Text] [Related]

  • 14. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, van Asselt ADI, Touw DJ, Aan Het Rot M, Schoevers RA.
    BMC Psychiatry; 2019 Nov 29; 19(1):375. PubMed ID: 31783823
    [Abstract] [Full Text] [Related]

  • 15. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD, Landrum RE, Moore MB, Szabo ST.
    J Clin Psychopharmacol; 2019 Nov 29; 41(5):594-599. PubMed ID: 34411009
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
    Capuzzi E, Caldiroli A, Capellazzi M, Tagliabue I, Marcatili M, Colmegna F, Clerici M, Buoli M, Dakanalis A.
    Int J Mol Sci; 2021 Aug 28; 22(17):. PubMed ID: 34502248
    [Abstract] [Full Text] [Related]

  • 17. Compounded intranasal racemic ketamine for major depressive disorder: A case report.
    Ziegler L, Peters E, Wanson A, Halpape K.
    Exp Clin Psychopharmacol; 2021 Dec 28; 29(6):750-754. PubMed ID: 33661659
    [Abstract] [Full Text] [Related]

  • 18. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB, Fedgchin M, Daly EJ, Drevets WC.
    Adv Pharmacol; 2020 Dec 28; 89():237-259. PubMed ID: 32616208
    [Abstract] [Full Text] [Related]

  • 19. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
    Sanders B, Brula AQ.
    J Psychiatr Res; 2021 May 28; 137():29-35. PubMed ID: 33647726
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
    Jawad MY, Di Vincenzo JD, Ceban F, Jaberi S, Lui LMW, Gillissie ES, Alnafeesi Y, Rosenblat JD, McIntyre RS.
    Expert Opin Drug Saf; 2022 Jun 28; 21(6):841-852. PubMed ID: 35387538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.